About Argonaut Manufacturing Services

Our Purpose

Everything Argonaut Manufacturing Services does is aimed at improving the human condition. With a culture that attracts highly talented people, innovating superior products and services, we help our partners exceed their goals in the world of health.

Like you, we Wanted a Better Solution for Contract Manufacturing

So we ventured out and created what we wanted most in a manufacturing service ourselves. We left our executive leader roles at Althea, Thermo Fisher, Affymetrix, Allergan, Ion Torrent, and other industry-leading organizations and built Argonaut Manufacturing Services to do Contract Manufacturing, Done Right.

We Understand, Because We Were in Your Shoes

A dream team with decades of experience has enabled us to design Argonaut Manufacturing Services to our high standards, with the customer in focus.

Built by Industry Leaders with Decades of Experience

Wayne Woodard

CEO / Board Member

Gayle Arnold

CFO

Chris Duffy

SVP/GM Biopharma Services

Jon Lenihan

SVP, Commercial Operations

Steve Folio

Vice President Quality and Regulatory Affairs

Stacy Sutton

SVP/GM Diagnostics & Life Sciences

Built in State-of-the-Art Facilities

Argonaut Manufacturing Services: 100,000 square feet in five separate buildings within 5 miles proximity in Carlsbad, CA

We’d love to give you a tour of our buildings. Let us know!

And an Engaged Board of Directors

Rick Hancock

With 34 years of life sciences experience in senior management, R&D, operations, and quality, Rick was most recently the CEO of Althea Technologies Inc. Prior to Althea Technologies he was the senior director of operations at The Immune Response Corporation. Rick has significant experience in cGMP manufacturing, regulatory affairs, scale up, operational protocols, and team management. He also worked at Hybritech as a quality control analyst, research associate, and laboratory supervisor.

Paul Grossman, Ph.D.

Before joining Telegraph Hill Partners, Paul Grossman was Head of Strategy and Corporate Development for Life Technologies, holding a similar position at Invitrogen Corporation prior to the merger with Applied Biosystems. Paul has held a variety of leadership and executive roles in R&D, Legal and Corporate Development teams, including spearheading the acquisition or divestment of more than 25 businesses

Alex Herzick

Before joining Telegraph Hill Partners, Alex worked at Genzyme Corporation in the Oncology / Multiple Sclerosis Business Development Group, where he sourced, evaluated, and executed strategic M&A and licensing biopharma transactions. Prior to Genzyme, he worked as a portfolio manager at BlueMountain Capital Management, and as an investment banking analyst at Bank of America Securities.

Todd Holmes

Todd is the Founder and Managing Partner of NewVale Capital LLC. He has more than 20 years of life science investing, company-building, and transaction experience across private and public sectors. Before founding NewVale, Todd led pharma and pharma services investing at CRG LP. Prior to CRG, he held senior investment roles with Gurnet Point Capital and Third Rock Ventures, helping to build and grow life science companies. Earlier in his career, he was an investor with BVF Partners, a biotechnology-focused hedge fund.

Scott Waldman

Scott has led and advised life sciences companies for more than 25 years with a focus on CDMOs since 2010. Scott consults for the pharma services industry and is an Operating Partner with NewVale Capital. Scott previously led M&A and corporate strategy as SVP of corporate development at Curia and as Chief Strategy Officer / Head of M&A at Lonza. Scott also served as US general counsel for Lonza and general counsel for Enzon Pharmaceuticals. He began his career as a corporate/M&A lawyer in New York at Sidley Austin and Weil, Gotshal & Manges.

Mark Nowakowski

With over 30 years of experience in lyophilization technologies, microchannel diagnostic cartridge design, and the founder of Lyogen LLC, Mark Nowakowski has joined the Argonaut team. Mark’s background is in molecular diagnostics and immunodiagnostics. He previously worked at Hybritech Incorporated, Biosite Diagnostics, FMC BioProducts, and Mesa Biotech with responsibilities including product design and manufacturing automation. When not conceiving novel cryodessication techniques, Mark can be found lacing up his running shoes and logging some miles.